Influence of rosuvastatin treatment on cerebral inflammation and nitro-oxidative stress in experimental lung injury in pigs.
Acute respiratory distress syndrome
Inflammation
Nitro-oxidative stress
Pigs
Rosuvastatin
Journal
BMC anesthesiology
ISSN: 1471-2253
Titre abrégé: BMC Anesthesiol
Pays: England
ID NLM: 100968535
Informations de publication
Date de publication:
13 09 2021
13 09 2021
Historique:
received:
18
03
2021
accepted:
28
08
2021
entrez:
14
9
2021
pubmed:
15
9
2021
medline:
8
2
2022
Statut:
epublish
Résumé
Many patients with acute respiratory distress syndrome (ARDS) suffer from cognitive impairment after hospital discharge. Different mechanisms have been implicated as potential causes for this impairment, inter alia cerebral inflammation. A class of drugs with antioxidant and anti-inflammatory properties are β-HMG-CoA-reductase inhibitors ("statins"). We hypothesized that treatment with rosuvastatin attenuates cerebral cytokine mRNA expression and nitro-oxidative stress in an animal model of acute lung injury. After approval of the institutional and state animal care committee, we performed this prospective randomized controlled animal study in accordance with the international guidelines for the care and use of laboratory animals. Thirty-two healthy male pigs were randomized to one of four groups: lung injury by central venous injection of oleic acid (n = 8), statin treatment before and directly after lung injury (n = 8), statin treatment after lung injury (n = 8), or ventilation-only controls (n = 8). About 18 h after lung injury and standardized treatment, the animals were euthanised, and the brains and lungs were collected for further examinations. We determined histologic lung injury and cerebral and pulmonal cytokine and 3-nitrotyrosine production. We found a significant increase in hippocampal IL-6 mRNA after lung injury (p < 0.05). Treatment with rosuvastatin before and after induction of lung injury led to a significant reduction of hippocampal IL-6 mRNA (p < 0.05). Cerebral 3-nitrotyrosine was significantly higher in lung-injured animals compared with all other groups (p < 0.05 vs. animals treated with rosuvastatin after lung injury induction; p < 0.001 vs. all other groups). 3-Nitrotyrosine was also increased in the lungs of the lung-injured pigs compared to all other groups (p < 0.05 each). Our findings highlight cerebral cytokine production and nitro-oxidative stress within the first day after induction of lung injury. The treatment with rosuvastatin reduced IL-6 mRNA and 3-nitrotyrosine concentration in the brains of the animals. In earlier trials, statin treatment did not reduce mortality in ARDS patients but seemed to improve quality of life in ARDS survivors. Whether this is attributable to better cognitive function because of reduced nitro-oxidative stress and inflammation remains to be elucidated.
Sections du résumé
BACKGROUND
Many patients with acute respiratory distress syndrome (ARDS) suffer from cognitive impairment after hospital discharge. Different mechanisms have been implicated as potential causes for this impairment, inter alia cerebral inflammation. A class of drugs with antioxidant and anti-inflammatory properties are β-HMG-CoA-reductase inhibitors ("statins"). We hypothesized that treatment with rosuvastatin attenuates cerebral cytokine mRNA expression and nitro-oxidative stress in an animal model of acute lung injury.
METHODS
After approval of the institutional and state animal care committee, we performed this prospective randomized controlled animal study in accordance with the international guidelines for the care and use of laboratory animals. Thirty-two healthy male pigs were randomized to one of four groups: lung injury by central venous injection of oleic acid (n = 8), statin treatment before and directly after lung injury (n = 8), statin treatment after lung injury (n = 8), or ventilation-only controls (n = 8). About 18 h after lung injury and standardized treatment, the animals were euthanised, and the brains and lungs were collected for further examinations. We determined histologic lung injury and cerebral and pulmonal cytokine and 3-nitrotyrosine production.
RESULTS
We found a significant increase in hippocampal IL-6 mRNA after lung injury (p < 0.05). Treatment with rosuvastatin before and after induction of lung injury led to a significant reduction of hippocampal IL-6 mRNA (p < 0.05). Cerebral 3-nitrotyrosine was significantly higher in lung-injured animals compared with all other groups (p < 0.05 vs. animals treated with rosuvastatin after lung injury induction; p < 0.001 vs. all other groups). 3-Nitrotyrosine was also increased in the lungs of the lung-injured pigs compared to all other groups (p < 0.05 each).
CONCLUSIONS
Our findings highlight cerebral cytokine production and nitro-oxidative stress within the first day after induction of lung injury. The treatment with rosuvastatin reduced IL-6 mRNA and 3-nitrotyrosine concentration in the brains of the animals. In earlier trials, statin treatment did not reduce mortality in ARDS patients but seemed to improve quality of life in ARDS survivors. Whether this is attributable to better cognitive function because of reduced nitro-oxidative stress and inflammation remains to be elucidated.
Identifiants
pubmed: 34517845
doi: 10.1186/s12871-021-01436-0
pii: 10.1186/s12871-021-01436-0
pmc: PMC8435760
doi:
Substances chimiques
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Rosuvastatin Calcium
83MVU38M7Q
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
224Informations de copyright
© 2021. The Author(s).
Références
Am J Respir Crit Care Med. 2015 Jan 1;191(1):71-8
pubmed: 25393331
Minerva Anestesiol. 2016 Nov;82(11):1230-1234
pubmed: 27232279
Curr Neurovasc Res. 2013 Nov;10(4):287-96
pubmed: 23937199
Neurochem Res. 2019 May;44(5):1065-1078
pubmed: 30820818
N Engl J Med. 2014 Jun 5;370(23):2191-200
pubmed: 24835849
J Chem Neuroanat. 2005 Oct;30(2-3):144-57
pubmed: 16122904
Brain Behav Immun. 2017 Jan;59:233-244
pubmed: 27633985
J Appl Physiol (1985). 2015 Dec 1;119(11):1245-61
pubmed: 26472873
Pulm Pharmacol Ther. 2016 Aug;39:85-91
pubmed: 27373439
Exp Neurol. 2015 Jan;263:235-43
pubmed: 25447937
Brain Res. 1991 Jun 7;550(2):257-62
pubmed: 1715805
BMC Pulm Med. 2015 Feb 07;15:7
pubmed: 25879802
Respir Res. 2014 Sep 06;15:101
pubmed: 25189285
Am J Respir Crit Care Med. 2012 Jun 15;185(12):1307-15
pubmed: 22492988
Adv Exp Med Biol. 2017;967:105-137
pubmed: 29047084
Am J Respir Crit Care Med. 2011 Mar 1;183(5):620-6
pubmed: 20870757
Am J Physiol Lung Cell Mol Physiol. 2008 Sep;295(3):L379-99
pubmed: 18621912
Thorax. 2016 May;71(5):401-10
pubmed: 26936876
Mol Neurobiol. 2018 Mar;55(3):2685-2695
pubmed: 28421541
Physiol Behav. 2017 Jun 1;175:56-65
pubmed: 28351559
Pharmacol Ther. 2017 Dec;180:90-98
pubmed: 28642115
J Neuroinflammation. 2015 Jun 06;12:114
pubmed: 26048578
J Crit Care. 2010 Sep;25(3):538.e7-12
pubmed: 20580199
J Vis Exp. 2018 Oct 26;(140):
pubmed: 30417861
PeerJ. 2020 Dec 9;8:e10471
pubmed: 33354426
Respir Care. 2011 Aug;56(8):1156-63
pubmed: 21396178
JAMA. 2016 Feb 23;315(8):788-800
pubmed: 26903337
Int J Clin Exp Med. 2015 Nov 15;8(11):21208-14
pubmed: 26885056
Intensive Care Med Exp. 2014 Dec;2(1):24
pubmed: 26266921
Crit Care. 2017 May 17;21(1):108
pubmed: 28511660
Oxid Med Cell Longev. 2013;2013:826143
pubmed: 23983901
Crit Care. 2010;14(6):1014
pubmed: 21211068
J Intensive Care. 2021 Jan 21;9(1):14
pubmed: 33478589
Crit Care. 2010;14(4):R143
pubmed: 20673352
Respir Res. 2006 Oct 11;7:125
pubmed: 17034639
J Med Microbiol. 2001 Sep;50(9):812-821
pubmed: 11549183
BMC Med. 2015 Jun 01;13:128
pubmed: 26033076
Respir Physiol Neurobiol. 2011 Dec 15;179(2-3):174-80
pubmed: 21855657
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
Cochrane Database Syst Rev. 2019 Jul 23;7:CD004477
pubmed: 31334568
J Comp Neurol. 2001 Jun 11;434(4):461-77
pubmed: 11343293
PLoS One. 2018 Aug 9;13(8):e0202131
pubmed: 30092082
Am J Respir Crit Care Med. 2013 Sep 15;188(6):693-702
pubmed: 23962032
Nat Rev Neurosci. 2008 Jan;9(1):46-56
pubmed: 18073775
Chem Biol Interact. 2019 Nov 1;313:108834
pubmed: 31545955
Mol Neurobiol. 2018 Feb;55(2):1045-1053
pubmed: 28092082
N Engl J Med. 2014 Sep 4;371(10):968-9
pubmed: 25184876
Shock. 2020 Jan;53(1):88-94
pubmed: 30724816
Anesth Analg. 2004 Jul;99(1):212-220
pubmed: 15281532
Stroke. 2008 Feb;39(2):433-8
pubmed: 18162625
Mediators Inflamm. 2015;2015:260465
pubmed: 26640323
Intensive Care Med. 2017 May;43(5):663-671
pubmed: 28004129
Crit Care Med. 2012 Jul;40(7):2022-32
pubmed: 22710202
Oxid Med Cell Longev. 2013;2013:963520
pubmed: 24381719
N Engl J Med. 2014 Oct 30;371(18):1695-703
pubmed: 25268516